ArticleViruses2018
Characterizing Phage Genomes for Therapeutic Applications.
Article in Viruses, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 177 citations in OpenAlex.
- Bacteriophage vB_SalS_KY05 controlsThe veterinary quarterly · 2026Article
- Escherichia coli bacteriophage vB_EcoS_MS2 effectively prevents biofilm formation but shows limited activity against mature biofilms.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Harnessing phage-ciprofloxacin synergy to overcome multidrug-resistant infections and biofilm persistence.Archives of microbiology · 2026Article
- Identification and Genomic Characterization of a Novel Teseptimavirus Species (vB_EcoP_S37A) and a Mosigvirus Phage (vB_EcoM_S37) Infecting Swine Extraintestinal PathogenicVeterinary sciences · 2026Article
- Bacteriophages AgainstViruses · 2026Review
- Characterization of a novel phage-plasmid vB_EcoM_ED targeting multidrug-resistant Escherichia coli isolates.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- A new Kayvirus vB_SauM-MUHD-1 combats Methicillin-resistant Staphylococcus aureus wound infections.Applied microbiology and biotechnology · 2026Article
- Artificial Intelligence in Bacteriophage Science: A Comprehensive Narrative Review of Applications, Challenges, and Translational Opportunities.Antibiotics (Basel, Switzerland) · 2026Review
- Isolation and characterization of a novel lytic phage Artin targeting typhoidal and nontyphoidal Salmonella and evaluation of its antibacterial efficacy in food.Virology journal · 2026Article
- Comparative morphological, genomic, and functional characterization of two newly isolated lytic caudoviricetes phages targeting Escherichia coli and Salmonella.Scientific reports · 2026Article
- Phage-antibiotic combination: a possible approach to combatting multidrug-resistant Klebsiella pneumoniae.AMB Express · 2026Article
- Review
- Isolation, characterization, and therapeutic assessment of novel phage vB_LSKP32 targeting KL64-type carbapenem-resistant Klebsiella pneumoniae.Archives of virology · 2026Article
- Phage-antibiotic synergistic effect for treating cutaneous wounds infections caused by MRSA and the assessment of wound healing biomarkers in a rabbit model.Scientific reports · 2026Article
- Genomic and in vitro characterization of two lytic bacteriophages infecting multidrug-resistant Erwinia sp. strain AnSW2-5.Scientific reports · 2026Article
- Combined bacteriophage and antibiotic therapy for refractory peritoneal dialysis-related peritonitis caused by Klebsiella pneumoniae.Nature communications · 2026Article
- Phage vB_AbaM_MU1 for biocontrol of carbapenem-resistant Acinetobacter baumannii (CRAB) isolated from wound infection.Virology journal · 2026Article
- Characterization and genome analysis of jumbo Escherichia phage UE-S1 and the antibacterial potential of its lysozyme against uropathogenic E. coli.BMC microbiology · 2025Article
- Colanic acid-mediated phage resistance enhances virulence in high-risk global clone Escherichia coli ST410.PLoS pathogens · 2025Article
- Therapeutic application of a jumbo bacteriophage against metallo-β-lactamase producing Pseudomonas aeruginosa clinical isolates.Journal of biomedical science · 2025Article
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multi-drug resistance is increasing at alarming rates. The efficacy of phage therapy, treating bacterial infections with bacteriophages alone or in combination with traditional antibiotics, has been demonstrated in emergency cases in the United States and in other countries, however remains to be approved for wide-spread use in the US. One limiting factor is a lack of guidelines for assessing the genomic safety of phage candidates. We present the phage characterization workflow used by our team to generate data for submitting phages to the Federal Drug Administration (FDA) for authorized use. Essential analysis checkpoints and warnings are detailed for obtaining high-quality genomes, excluding undesirable candidates, rigorously assessing a phage genome for safety and evaluating sequencing contamination. This workflow has been developed in accordance with community standards for high-throughput sequencing of viral genomes as well as principles for ideal phages used for therapy. The feasibility and utility of the pipeline is demonstrated on two new phage genomes that meet all safety criteria. We propose these guidelines as a minimum standard for phages being submitted to the FDA for review as investigational new drug candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.